Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
European Journal of Radiology|July 1, 2008
Imaging-therapy computed tomography with quasi-monochromatic X-raysGregor Jost, Sven Golfier, Ruediger Lawaczeck, et al.
Experimental Cell Research|February 1, 2014
3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regionsCarsten Wenzel, Björn Riefke, Stephan Gründemann, et al.
Molecular Cancer Therapeutics|April 10, 2014
Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effectSven Golfier, Charlotte Kopitz, Antje Kahnert, et al.
Cancer Immunology Research|April 22, 2020
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2)Julia Huetter, Uwe Gritzan, Ilona Gutcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2019
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive CancersUrs B Hagemann, Christine Ellingsen, Joachim Schuhmacher, et al.
Molecular Cancer Therapeutics|October 5, 2019
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer ModelsAntje M Wengner, Gerhard Siemeister, Ulrich Lücking, et al.
Molecular Cancer Therapeutics|March 16, 2017
Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung CancerJörg Willuda, Lars Linden, Hans-Georg Lerchen, et al.
Cancer Discovery|October 15, 2025
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung CancerFranziska Siegel, Stephan Siegel, Kristýna Kotýnková, et al.
Oncoimmunology|February 10, 2022
T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interactionJessica Pinkert, Hans-Henning Boehm, Mark Trautwein, et al.
Cell Chemical Biology|March 27, 2024
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signalingKeith Graham, Philip Lienau, Benjamin Bader, et al.
Pageof 2